In English | En español
Questions About Cancer? 1-800-4-CANCER

Featured Clinical Trials

Highlighted NCI-Supported Cancer Studies < Back to Main
  • Posted: 02/07/2006

Page Options

  • Print This Page
  • Email This Document

Search Featured Trials

Targeted Treatment for Cutaneous T-Cell Lymphoma

Name of the Trial

Phase II Study of LMB-2 Immunotoxin in Patients With CD25-Positive Cutaneous T-Cell Lymphoma (NCI-04-C-0142). See the protocol summary.

Principal Investigator

Dr. Robert J. Kreitman, NCI Center for Cancer Research.

Why This Trial Is Important

Dr. Robert J. Kreitman
Dr. Robert J. Kreitman
Principal Investigator

Cutaneous T-cell lymphoma (CTCL) is a type of non-Hodgkin's lymphoma that includes mycosis fungoides and Sezary syndrome. CTCL is caused when cancerous T lymphocytes (or T cells) migrate out of blood vessels and invade the skin, where they give rise to a variety of abnormalities, including thickened skin plaques, reddening, and, at more advanced stages, malignant tumors.

In the most advanced stages, cancerous T cells spread into the lymphatic system and internal organs. CTCL is highly treatable when diagnosed at its earliest stages, but there is no curative treatment available for advanced disease.

Researchers are testing the effectiveness of an immunotoxin called LMB-2 in killing CTCL cells. LMB-2 is a laboratory-created monoclonal antibody fragment attached to a bacterial toxin. It binds to a protein called CD25, which is found on the surface of many human lymphocytes.

CD25 is also present on CTCL cells in approximately half of all cases, where it appears more abundantly than on normal lymphocytes. The greater abundance of CD25 allows LMB-2 to target malignant T lymphocytes with great specificity. Once LMB-2 binds to CD25 on the cell surface, the toxin is taken up by the lymphocytes, causing them to die.

Patients will receive up to six courses of LMB-2 over approximately six months, providing their disease does not progress. Patients who respond completely to LMB-2 may receive further treatment.

"In a phase I trial of LMB-2 that involved patients with a variety of hematologic malignancies," said Dr. Kreitman, "the only patient with CTCL had a clinically significant partial response lasting more than six months."

Who Can Join This Trial

Researchers will enroll 16 to 27 patients aged 18 and older and diagnosed with advanced-stage CD25-positive CTCL. See the complete list of eligibility criteria.

Study Site and Contact Information

The trial is taking place at the NIH Clinical Center in Bethesda, Maryland. For more information, contact the NCI Clinical Studies Support Center at 1-888-NCI-1937. The toll-free call is confidential.